# Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas

> **NCT05105412** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 12 (actual)

## Conditions studied

- Peripheral T-cell Lymphomas (PTCL)

## Interventions

- **DRUG:** Lenalidomide and Gemcitabine (Dose level 11)
- **DRUG:** Lenalidomide and Gemcitabine (Dose level 21)
- **DRUG:** Lenalidomide and Gemcitabine (Dose level 31)
- **DRUG:** Lenalidomide and Gemcitabine (Dose level 41)

## Key facts

- **NCT ID:** NCT05105412
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-15
- **Primary completion:** 2024-03-30
- **Final completion:** 2024-03-30
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** The resolution of DSMB
- **Last updated:** 2024-07-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05105412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05105412, "Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05105412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*